Business
AstraZeneca begins trading on NYSE
AstraZeneca has commenced trading its ordinary shares on the New York Stock Exchange, aligning its listing structure across the NYSE, London Stock Exchange, and Nasdaq Stockholm. This move aims to provide broader access to the US capital market and facilitate greater investor participation in the company's growth, which saw new pipeline readouts representing over $10 billion in peak revenue opportunity last year. AstraZeneca maintains its 2030 ambition to grow annual revenue to $80 billion and launch 20 new medicines, with continued investment in transformative technologies. The company's ordinary shares will continue to trade under the ticker "AZN" on all three exchanges, with its UK and Swedish listings remaining unaffected. Disclaimer*
About this update from Astrazeneca Plc
[{"type":"text","content":"\n\n \n02 February 2026\n \nAstraZeneca begins trading on the New York Stock Exchange\n \nOrdinary shares now trade across the NYSE, LSE and STO under a harmonised global listing structure\n \nAstraZeneca today begins trading its ordinary shares on the New York Stock Exchange (NYSE) for the first time, enabling more US investors to participate in the Company's strong growth. With this change the trading of AstraZeneca ordinary shares is now aligned across the NYSE, the London Stock Exchange (LSE) and Nasdaq Stockholm (STO) under a harmonised listing structure.\nMichel Demaré, Chair, AstraZeneca, said: \"Today marks the start of an exciting new period for AstraZeneca, one which we believe gives broader access to the largest capital market in the world. This will allow even more investors to participate in AstraZeneca's future. Our harmonised listing across New York, London and Stockholm reflects strong shareholder support for our growth strategy and positions AstraZeneca to deliver more innovative medicines to more patients around the world.\"\nLynn Martin, President, NYSE Group said: \"Today we are proud to welcome AstraZeneca to the NYSE, where it joins a community of groundbreakers and industry leaders. Through its listing on the world's largest and most liquid capital market, the company is well-positioned to expand its global investor base and accelerate its commitment to delivering innovation to patients and the wider biopharmaceutical industry.\"\nAstraZeneca's strong growth is driven both by its global reach and diverse sources of business. Last year was a catalyst-rich period with new pipeline readouts collectively representing a peak revenue opportunity of over $10 billion. With this momentum continuing into 2026, the Company has confidence in reaching its 2030 ambition to grow annual revenue to $80bn and launch 20 new medicines. Looking beyond 2030, AstraZeneca is investing in transformative technologies that have the potential to change the practice of medicine across our portfolio.\nAstraZeneca ordinary shares will continue to trade under the ticker symbol \"AZN\" across the three exchanges. The Company's listing in the UK on the LSE and in Sweden on the STO are unaffected by the move and remain included in the FTSE 100 and OMX Stockholm 30 indices.\nThe prior listing of American Deposit...